Bristol Myers Squibb (NYSE:BMY) Research Coverage Started at Royal Bank Of Canada

Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb (NYSE:BMY) in a research report sent to investors on Tuesday, MarketBeat.com reports. The firm issued a sector perform rating and a $60.00 price target on the biopharmaceutical company’s stock.

BMY has been the topic of a number of other reports. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. HSBC reiterated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Scotiabank reissued a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $60.71.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $61.10 on Tuesday. The company has a market cap of $124.43 billion, a price-to-earnings ratio of 17.71, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33. The stock’s 50 day simple moving average is $56.81 and its two-hundred day simple moving average is $50.41. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period last year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Institutional Trading of Bristol Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp grew its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after acquiring an additional 1,385,206 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares during the period. Geode Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $1,947,272,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — a potentially high-value ADC Bristol Myers licensed from China that management has flagged as central to future growth. This outcome materially de‑riskes a late‑stage asset that could drive long‑term revenue and milestone upside. SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza‑bren)
• Positive Sentiment: Clinical pipeline progress beyond Iza‑bren: BMY advanced a pediatric lymphoma combination study, signaling additional, smaller near‑term clinical catalysts and “quiet upside” opportunities that can support incremental valuation gains if data readouts continue to be constructive. Bristol‑Myers Squibb Advances Pediatric Lymphoma Combo
• Neutral Sentiment: Positive press pieces from stock‑style outlets (Zacks) highlight BMY as a value and momentum name, which may attract different investor audiences but do not represent new company fundamentals or catalysts. Bristol Myers Squibb (BMY) is a Top‑Ranked Momentum Stock
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target — slightly below current levels — which can temper upside from momentum traders and suggests limited near‑term upside in RBC’s view. RBC Capital Initiates Bristol Myers with $60 Target
• Negative Sentiment: Recent quarterly results showed an EPS miss (Q4 EPS $1.26 vs. $1.65 expected) despite a slight revenue beat; management set FY2026 EPS guidance of $6.05–$6.35. The earnings miss and the still‑high leverage (debt/equity ~2.3) remain near‑term headwinds that can pressure the stock until growth visibility improves. Bristol Myers Squibb – recent earnings and metrics

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.